期刊文献+

四硫化四砷STI571和除莠霉素诱导K562细胞凋亡的研究(英文) 被引量:1

Induction of apoptosis in K562 human chronic myelogenous leukemia cells by tetra-arsenic tetra-sulfide, STI571 and herbimycin
下载PDF
导出
摘要 目的 目前慢性粒细胞性白血病 (CML)的化疗效果仍不理想 ,为寻找对CML敏感的药物 ,该研究探讨四硫化四砷、STI5 71和除莠霉素对CML细胞株K5 6 2的作用。方法 通过MTS方法检测三种药物在不同浓度 (0 .0 1 ,0 .1 ,1 .0 ,2 .0 ,5 .0 ,1 0 .0 μmol/L)下对K5 6 2细胞活力的影响。采用瑞氏染色、荧光染色和琼脂糖凝胶电泳观察药物处理后细胞形态学的变化和细胞凋亡的发生。用流式细胞仪检测细胞凋亡率。结果 用 5 .0 μmol/L的四硫化四砷、STI5 71和除莠霉素培养 3天 ,K5 6 2细胞活力明显下降 ,其吸光值分别为 0 .32± 0 .0 4 ,0 .4 9± 0 .0 1 ,0 .6 9± 0 .0 2 ,其中四硫化四砷和STI5 71对细胞的抑制作用强于除莠霉素 (P <0 .0 1 ) ,前两者间无明显差异 (P >0 .0 5 )。 1 .0 ,5 .0 ,1 0 .0 μmol/L的四硫化四砷对K5 6 2细胞的抑制作用呈时间依赖关系 (P <0 .0 1 )。小于 1 .0μmol/L的四硫化四砷对K5 6 2细胞活力无明显影响。四硫化四砷培养 2 4至 4 8小时后 ,K5 6 2细胞出现染色质浓缩、核碎片及凋亡小体等典型的凋亡形态学改变。用 5 .0 μmol/L的四硫化四砷、STI5 71和除莠霉素培养 72小时后 ,K5 6 2细胞的凋亡率分别为 6 8.8%、5 6 .7%和 35 .5 % ,2 .0与 3.0 μmol/L的四硫化四砷诱导K5 6 2细胞凋? Objective The therapeutic effect of chronic myeloid leukemia (CML) is undesirable. In order to find a new sensitive drug for CML, this study aims at exploring the effects of tetra arsenic tetra sulfide (As 4S 4) on human leukemia K562 cells. Methods The viability of K562 cells, represented by absorbance, was measured by MTS assay. The cells morphological changes were determined by Wright's staining and Hoechst33342 assay. The cell apoptosis was evaluated by DNA agarose gel electrophoresis and the cell apoptosis rate was measured by flow cytometry. Results The cell viability decreased significantly being cultured with 5.0 μmol/L As 4S 4, STI571 and herbimycin for 72 hrs (with absorbances of 0.32 ± 0.04 , 0.49 ± 0.01 and 0.69 ± 0.02 , respectively). As 4S 4 and STI571 had more inhibition on the K562 cells viability than herbimycin (P< 0.01 ), and there was no statistically significant difference between that of As 4S 4 and STI571. The effects of 1.0, 5.0 and 10.0 μmol/L As 4S 4 on K562 cells were time dependent. When the concentration was lower than 1.0 μmol/L, As 4S 4 had little effect on K562 cells. After being cultured with 2.0 μmol/L As 4S 4 for 24 to 48 hrs, typical morphological changes of apoptosis appeared in the K562 cells. After being cultured with 5.0 μmol/L As 4S 4, STI571 and herbimycin for 72 hrs, the apoptosis rate of K562 cells were 68.8%, 56.7% and 35.5%, respectively. When the concentrations of As 4S 4 changed from 2.0 to 3.0 μmol/L, the apoptosis rate increased from 25.7% to 45.3%. There was no significant difference between the apoptosis rate of K562 cells induced by 5.0 and 10.0 μmol/L As 4S 4. Conclusions As 4S 4 with the concentration of 2.0 μmol/L could inhibit the growth of K562 cells efficiently through inducing apoptosis.
出处 《中国当代儿科杂志》 CAS CSCD 2004年第1期15-18,F003,共5页 Chinese Journal of Contemporary Pediatrics
基金 ShanghaiScienceandTechnologyFoundation (No :0 2DJ14 0 11)
关键词 四硫化四砷 STl571 除莠霉素 K562 细胞凋亡 慢性粒细胞性白血病 CML 化疗 Tetra arsenic tetra sulfide STI 571 Herbimycin K562 Apoptosis
  • 相关文献

参考文献9

  • 1Dao-Pei Lu,Jing-Ying Qiu,Bin Jiang,Qin Wang,Kai-Yan Liu,Yan-Rong Liu,et al.Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report[].Blood.2002
  • 2Francesco T,marilyn DA,Audrey YF,Karen P.Model of inhibition of the NPM-ALK kinase activity by herbimycin A[].Clinical Cancer Research.2002
  • 3Bedi A,Zehnbauer BA,Barber JP,Sharkis SJ,Jones RJ.Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia[].Blood.1994
  • 4Hong-Mei Jing,Yukihiro Shimizu,Xiao-Yan Ke,Yoshiro Kashii,Akiharu Watanabe.Effect of arenic trioxide on different cell lines derived from chronic myeloid leukemia[].Experimental Hematology.2002
  • 5Silver RT,Woolf SH,Hehlmann R,Appelbaum FR,Anderson J,Bennett C,et al.An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemias: developed for the American Society of Hematology[].Blood.1999
  • 6Xuemei SUN,Judith EL,Andrew E,Graham JL.Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571[].Blood.2001
  • 7Michael WD,John MG,Nicholas L,Junia VM.The tyrosine kinase inhibitor CGP5714B selectively inhibits the growth of BCRABL-positive cells[].Blood.1997
  • 8Shimoni A,Kroger N,Zander AR,Rowe JM,Hardan I,Avigdor A,et al.Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias[].Leukemia.2003
  • 9Chen GQ,Zhu J,Shi XG,Ni JH,Zhong HJ,Si GY,et al.In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2 O3 ) in the treatment of acute promyelocytic leukemia:As2 O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins[].Blood.1996

同被引文献10

  • 1佟海侠,张继红,马力,陆春伟,张锦华.Caspase-8和DR5在TRAIL诱导神经母细胞瘤细胞凋亡中的作用[J].中国当代儿科杂志,2006,8(4):327-330. 被引量:4
  • 2Marx J.Cell biology.Ubiquitin lives up to its name[J].Science,2002,297 (5588):1792-1794.
  • 3Cervello M,Giannitrapani L,La Rosa M,Notarbartolo M,Labbozzetta M,Poma P,et al.Induction of apoptosis by the proteasome inhibitor MGI32 in human HCC cells:Porssible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-calenin-mediated transactivation[J].Int J Mol Med,2004,13(5):7412748.
  • 4Kari n M,Cao Y,Greten FR,Li ZW.NF-kappaB in cancer:from innocent bystander to major culprit[J].Nat Rev Cancer,2002,2 (4):301-310.
  • 5Blad6 J,Cibeira MT,Rosinol L.Bortezomib:a valuable new antineoplastic strategy in multiple myeloma[J].Aeta Oncol,2005,44(5):440-448.
  • 6Smith GG.Proteasome inhibition in eaneer therapy[J].J Infus Nurs,2005,28(4):258-264.
  • 7Hochwald SN,Lind DS,Malaty J,Copeland EM 3rd,Moldawer LL,MacKay SL.Antineoplastie therapy in colorectal cancer through proteasome inhibition[J].Am Surg,2003,69(1):15-23.
  • 8Kim DS,Kim SY,Jeong YM,Jean SE,Kim MK,Kwon SB,et al.Light-activated indole-3-acetie acid induces apoptosis in g361 human melanoma cells[J].Biol Pharm Bull,2006,29 (12):2404-2409.
  • 9Rajkumar SV,Richardson PC;,Hideshima T,Anderson KC.Proteaanme inhibition as a novel therapeutic target in human cancer[J].J Clin Oncol,2005,23(3):630-639.
  • 10Guzman ML,Neering SJ,Upchurch D,Grimes B,Howard DS,Rizzieri DA,et al.Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells[J].Blood,2001,98(8):2301-2307.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部